Dr Andreas Rummelt joined the Board following AstraZeneca’s acquisition of Alexion, where he had been a Board member from 2010. He has more than 20 years' experience in executive management positions in the pharmaceutical industry. His international career has focused on technical research and development, manufacturing and quality. Andreas was previously at Novartis where he had been Group Head of Technical Operations and Quality of the Pharmaceuticals Division and, from 2006 until 2010, served on the Executive Committee. He also served as Global Chief Executive Officer of Sandoz, its Generics Division from 2004 to 2008, having originally joined Sandoz Pharma in 1985. Andreas is a pharmacist and earned his PhD in pharmaceutical sciences from the University of Erlangen-Nuremberg, Germany. He received his executive training in general management and leadership from IMD in Lausanne, Switzerland; INSEAD in Fontainebleau, France; and Harvard Business School in Cambridge, MA, US.
Andreas is Chairman and Managing Partner of InterPharmaLink AG, a management consulting firm based in Basel, Switzerland and member of the boards of various privately-held biotech and pharmaceutical companies in Europe. He is also member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership based in Geneva, Switzerland.
